[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"calcific-uremic-arteriolopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:calcific-uremic-arteriolopathy":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100632253","calciphylaxis-in-patients-with-chronic-kidney-disease---a-study-of-the-danish-calciphylaxis-research-initiative-dancari-100632253",false,"NCT07511283","Calciphylaxis in Patients With Chronic Kidney Disease - A Study of the Danish Calciphylaxis Research Initiative (DanCaRI)","Inclusion Criteria:\n\nCases\n\n* Age ≥18 years.\n* CKD.\n* Suspicion of calciphylaxis or newly diagnosed calciphylaxis episode. The suspicion or diagnosis of calciphylaxis is a mutual decision of the involved medical specialties (nephrologist, dermatologist, pathologist, other).\n* Ability to give informed consent.\n* Ability to participate in a clinical study as assessed by the local investigator.\n* Provides written informed consent.\n\nControls\n\n* Age ≥18 years.\n* CKD\n* Ability to give informed consent.\n* Ability to participate in a clinical study as assessed by the local investigator.\n* Provides written informed consent.\n\nHealthy reference group\n\n* Age ≥18 years.\n* Self-assessed as healthy, confirmed by local investigators at inclusion\n\nExclusion Criteria:\n\nCases\n\n\\- the calciphylaxis diagnosis becomes excluded\n\nControls - Being diagnosed with calciphylaxis\n\nHealthy controls Up to 60 years of age: eGFR below 60 ml\u002Fmin\u002F1.72m2.\n\n\\- Over 60 years of age: eGFR below the 95% confidence interval for eGFR adjusted for age (Danish Society of Nephrology references ranges)",true,"ALL","18 Years",{"count":19,"type":20},860,"ESTIMATED","OBSERVATIONAL","Calciphylaxis is a rare yet life-threatening condition involving pronounced calcification in small blood vessels of the skin.\n\nKnowledge about its underlying mechanisms and contributing risk factors remains limited. Chronic kidney disease is one of the strongest disease predictors. No evidence based effective therapy is currently available. Research on the topic is mainly hindered by the condition's rarity.\n\nThe study Calciphylaxis in patients with chronic kidney disease - A study of the Danish Calciphylaxis Research Initiative (DanCaRI) is set up to facilitate the systematic retrospective and prospective comparison of patients with chronic kidney disease and calciphylaxis to matched patients with chronic kidney disease who did not develop calciphylaxis thereby providing new knowledge that can support prevention, early detection, and new treatment approaches.",[24,25,26,27,28],"Calciphylaxis","Calcific Uremic Arteriolopathy","End Stage Renal Disease (ESRD)","Chronic Kidney Diseases","Nephrogenic Calciphylaxis",[24,25,28,30,27],"End Stage Renal Disease","RECRUITING","2026-03-30",{"date":34,"type":35},"2026-04-06","ACTUAL",{"date":37,"type":20},"2026-04",{"date":39,"type":20},"2040-06",{"name":41,"class":42},"Odense University Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":43},"100407991","early-phase-1-human-amniotic-derived-mesenchymal-stem-cell-therapy-for-calciphylaxis-100407991","NCT04592640","Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis","Effects of Human Amniotic-derived Mesenchymal Stem Cells (hAMSCs) on Calciphylaxis Patients: An Open-Label Single-Arm Study","Inclusion Criteria:\n\n1. 18-75 years old.\n2. Clinical diagnosis of calciphylaxis, including patients with chronic kidney disease who did not or had regular dialysis (hemodialysis or peritoneal dialysis).\n3. All subjects signed informed consent.\n\nExclusion criteria:\n\n1. Patients who refuse to sign informed consent.\n2. Patients with malignant tumors or severe psychiatric disorders, or an expected survival time of less than 6 months.\n3. Pregnant or lactating women of childbearing age.\n4. Participation in another clinical trial with an experimental drug within 90 days prior the inclusion.","75 Years",{"count":53,"type":20},9,"INTERVENTIONAL",[56],"EARLY_PHASE1","Treatment for Calciphylaxis Patients with Human Amniotic-derived Mesenchymal Stem Cells",[27,24,25,59,60,61],"Treatment","Safety","Efficacy",[27,24,25,63,64,60,61],"Human Amniotic-derived Mesenchymal Stem Cells","Rare disease (ORPHA280062)","2026-03-02",{"date":67,"type":35},"2026-03-04",{"date":69,"type":35},"2018-09-17",{"date":71,"type":20},"2028-09-17",{"name":73,"class":42},"The First Affiliated Hospital with Nanjing Medical University",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":84,"studyType":21,"phases":4,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":43},"100288294","partners-calciphylaxis-biobank-100288294","NCT03032835","Partners Calciphylaxis Biobank","Partners Calciphylaxis Biobank and Patient Registry","PCB","Inclusion Criteria:\n\n1. Male or female ≥18 years old\n2. Skin lesions consistent with calciphylaxis diagnosis as determined by the treating clinician\n3. Informed of the investigational nature of the study and sign written Informed consent OR are eligible for surrogate consent process based on impaired decision making\n\nExclusion Criteria:\n\n1. Patients \\\u003C18 years of age\n2. Prisoners",{"count":83,"type":20},300,"20 Years","Calciphylaxis, a vascular calcification disorder, is a rare and serious disorder characterized by calcification of dermal arterioles.\n\nThere are significant gaps in the understanding of the pathophysiology and risk factors for calciphylaxis. At present, there is no effective treatment. Uncertain pathobiology, rare incidence and lack of collaborative approach have been some of the major limiting factors towards treating calciphylaxis.\n\nThe Partners Calciphylaxis Biorepository (PCB) aims to address these gaps within calciphylaxis research by utilizing existing and, when necessary, developing new infrastructure to support the consent of patients and the collection of dedicated samples for a calciphylaxis repository.",[24,25,30,27],[24,88,89],"Warfarin","Dialysis","2024-11-18",{"date":92,"type":35},"2024-11-19",{"date":94,"type":4},"2017-01",{"date":96,"type":20},"2030-12",{"name":98,"class":42},"Massachusetts General Hospital"]